- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05714202
Une étude sur le TAR-200 en association avec le cétrélimab ou le TAR-200 seul par rapport au bacille de Calmette-Guérin (BCG) intravésical chez des participants atteints d'un cancer de la vessie non invasif musculaire à haut risque et naïfs au BCG (SunRISe-3)
Une étude de phase 3, ouverte, multicentrique et randomisée évaluant l'efficacité et l'innocuité du TAR-200 en association avec le cetrelimab ou le TAR-200 seul par rapport au bacille intravésical de Calmette-Guérin (BCG) chez des participants à haut risque naïfs au BCG Cancer de la vessie non invasif musculaire
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG. The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total duration of the study will be up to 5 years and 2 months. Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the study.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Accès étendu
Contacts et emplacements
Lieux d'étude
-
-
-
Cologne, Allemagne, 50968
- Urologische Partnerschaft Koln UPK
-
Duisburg, Allemagne, 47169
- Urologicum Duisburg
-
Erlangen, Allemagne, 91054
- Universitatsklinikum Erlangen
-
Essen, Allemagne, 45147
- Universitatsklinikum Essen
-
Frankfurt am Main, Allemagne, 60590
- Universitaetsklinikum Frankfurt
-
Freiburg im Breisgau, Allemagne, 79106
- Universitaetsklinikum Freiburg
-
Markkleeberg, Allemagne, 04416
- Matthias Schulze - Germany
-
Mettmann, Allemagne, 40822
- Urologie Neandertal Praxis Mettmann
-
München, Allemagne, 81675
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Münster, Allemagne, 48149
- Universitatsklinikum Munster
-
Nuremberg, Allemagne, 90491
- Medizinisches Versorgungszentrum - Urologie
-
Nuremberg, Allemagne, 90419
- Klinikum Nurnberg Nord
-
Nürtingen, Allemagne, 72622
- Studienpraxis Urologie Nurtingen
-
Regensburg, Allemagne, 93053
- Caritas-Krankenhaus St. Josef
-
Tübingen, Allemagne, 72076
- Universitat Tubingen
-
-
-
-
-
Buenos Aires, Argentine, C1199
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentine, C1417
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
Córdoba, Argentine, X5016KEH
- Hospital Privado Centro Medico de Cordoba
-
Córdoba, Argentine, 5000
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Córdoba, Argentine, X5000KPH
- Centro Urologico Profesor Bengio
-
Mar del Plata, Argentine, B7602CBM
- Hospital Privado de la Comunidad
-
Río Cuarto, Argentine, 5800
- Instituto Medico Rio Cuarto
-
-
-
-
-
Heidelberg, Australie, 3084
- Austin Health
-
Macquarie University, Australie, 2109
- Macquarie University Hospital
-
Nedlands, Australie, 6009
- Hollywood Private Hospital
-
South Brisbane, Australie, 4101
- Mater Hospital Brisbane
-
-
-
-
-
Antwerp, Belgique, 2020
- ZNA Middelheim
-
Bruges, Belgique, 8000
- AZ Sint-Jan
-
Bruges, Belgique, 8310
- AZ Sint-Lucas
-
Ghent, Belgique, 9000
- AZ Maria Middelares
-
Ghent, Belgique, 9000
- UZ Gent
-
Libramont-Chevigny, Belgique, 6800
- Centre Hospitalier de l'Ardenne
-
Roeselare, Belgique, 8800
- AZ Delta
-
Sint-Niklaas, Belgique, 9100
- Vitaz
-
Wilrijk, Belgique, 2610
- GZA Ziekenhuizen- Campus St Augustinus
-
-
-
-
-
Barretos, Brésil, 14784-400
- Fundacao Pio XII
-
Bauru, Brésil, 17033-495
- NAIC Nair Antunes Instituto do Cancer
-
Campinas, Brésil, 13083-888
- Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
-
Curitiba, Brésil, 81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Natal, Brésil, 59075-740
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brésil, 90050-170
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Presidente Prudente, Brésil, 19013-050
- Hospital Regional do Cancer Hospital de Esperanca
-
Salvador, Brésil, 41253-190
- IDOR - Regional Bahia
-
Santa Cruz do Sul, Brésil, 96835-090
- Hospital Ana Nery Santa Cruz do Sul
-
Santo André, Brésil, 09060-870
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brésil, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brésil, 01246 000
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, Brésil, 05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brésil, 1321 001
- Real e Benemerita Associacao Portuguesa de Beneficencia
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Nova Scotia Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St Josephs Healthcare Hamilton
-
Toronto, Ontario, Canada, M5G 1Z5
- Princess Margaret Cancer Centre University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3E4
- CHUM - Centre hospitalier universitaire de Montreal
-
Québec, Quebec, Canada, G1J1Z4
- CHU de Quebec Universite Laval Hopital de l Enfant Jesus
-
Saint Jerome Quebec, Quebec, Canada, J7Z 2V4
- Unite de Recherche Clinique du CISSS des Laurentides
-
-
-
-
-
Beijing, Chine, 100730
- Beijing Hospital
-
Beijing, Chine, 100034
- Peking University First Hospital
-
Beijing, Chine, 101100
- Beijing Luhe Hospital, Capital Medical University
-
Changchun, Chine, 130499
- The First Bethune Hospital of Jilin University
-
Changsha, Chine, 410013
- Hunan Province Cancer Hospital
-
Chengdu, Chine, 610044
- West China Hospital Sichuan University
-
Chongqing, Chine, 400000
- Chongqing University Cancer Hospital
-
Deyang, Chine, 618000
- People's Hospital of Deyang City
-
Guangzhou, Chine, 430030
- Sun Yat Sen University Cancer Center
-
Hangzhou, Chine, 310000
- Zhejiang Provincial People's Hospital
-
Hangzhou, Chine, 310016
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanjing, Chine, 210008
- Nanjing Drum Tower Hospital
-
Ningbo, Chine, 315010
- The First Affiliated Hospital of Ningbo University
-
Shanghai, Chine, 200025
- Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
-
Shanghai, Chine, 200400
- Huadong Hospital Affiliated to Fudan University
-
Shenyang, Chine, 110004
- Shengjing Hospital Of China Medical University
-
Tianjin, Chine, 300211
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Chine, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Chine, 430030
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
-
Xi'an, Chine, 710061
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University
-
Yantai, Chine, 264000
- Yantai Yuhuangding Hospital
-
Zhengzhou, Chine, 450008
- Henan Cancer Hospital
-
-
-
-
-
Busan, Corée du Sud, 49241
- Pusan National University Hospital
-
Cheongju-si, Corée du Sud, 28644
- Chungbuk National University Hospital
-
Daegu, Corée du Sud, 41404
- Kyungpook National University Chilgok Hospital
-
Daegu, Corée du Sud, 42601
- Keimyung University Dongsan Hospital
-
Gyeonggi-do, Corée du Sud, 10408
- National Cancer Center
-
Jeollanam-do, Corée du Sud, 58128
- Chonnam National University Hwasun Hospital
-
Seoul, Corée du Sud, 03080
- Seoul National University Hospital
-
Seoul, Corée du Sud, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Corée du Sud, 06351
- Samsung Medical Center
-
Seoul, Corée du Sud, 03181
- Kangbuk Samsung Hospital
-
Seoul, Corée du Sud, 06591
- The Catholic University of Korea Seoul St Marys Hospital
-
Seoul, Corée du Sud, 02841
- Korea University Anam Hospital
-
-
-
-
-
A Coruña, Espagne, 15006
- Hosp Univ A Coruna
-
Algeciras, Espagne, 11207
- Hosp. Punta de Europa
-
Barcelona, Espagne, 08025
- Fund. Puigvert
-
Cadiz, Espagne, 11009
- Hosp. Puerta Del Mar
-
Castellon, Espagne, 12004
- Hosp. Gral. Univ. de Castellon
-
L'Hospitalet de Llobregat, Espagne, 08907
- Hosp. Univ. de Bellvitge
-
Lugo, Espagne, 27003
- Hosp. Univ. Lucus Augusti
-
Madrid, Espagne, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Espagne, 28046
- Hosp. Univ. La Paz
-
Madrid, Espagne, 28027
- Clinica Univ. de Navarra
-
Málaga, Espagne, 29010
- Hosp Virgen de La Victoria
-
Santander, Espagne, 39008
- Hosp. Univ. Marques de Valdecilla
-
Valencia, Espagne, 46010
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
Bordeaux, France, 33000
- Polyclinique Bordeaux Nord Acquitaine
-
Clermont-Ferrand, France, 63003
- CHU Gabriel-Montpied
-
Grenoble, France, 38043
- CHU Grenoble
-
Limoges, France, 87000
- Polyclinique de Limoges - Francois Chenieux
-
Lyon, France, 69437
- Hôpital Edouard Herriot
-
Nantes, France, 44093
- CHU de Nantes hotel Dieu
-
Nîmes, France, 30029
- CHU Nimes
-
Orléans, France, 45067
- Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
-
Paris, France, 75013
- Hôpital Universitaire Pitié-Salpêtrière
-
Paris, France, 75018
- APHP - Hopital Bichat - Claude Bernard
-
Paris, France, 75960
- Groupe Hospitalier Diaconesses Croix Saint Simon
-
Paris, France, 75015
- Hopital Europeen Georges-Pompidou
-
Quint-Fonsegrives, France, 31130
- Clinical La Croix Du Sud - Ramsay Santé
-
Rennes, France, 35000
- Chu Rennes Hopital Pontchaillou
-
Strasbourg, France, 67200
- Institut de Cancerologie Strasbourg Europe ICANS
-
Toulouse, France, 31059
- CHU Rangueil
-
-
-
-
-
Bangalore, Inde, 560027
- Health Care Global Enterprises pvt Ltd
-
Chandigarh, Inde, 160012
- Post Graduate Institute of Medical Education And Research PGIMER
-
Gurugram, Inde, 122001
- Artemis Hospital
-
Kolkata, Inde, 700094
- Netaji Subhas chandra Bose Cancer Research Institute
-
Mumbai, Inde, 400012
- Tata Memorial Hospital
-
Pune, Inde, 411040
- CIMET s Inamdar Multispeciality Hospital
-
-
-
-
-
Acquaviva delle Fonti, Italie, 70021
- Generale Regionale F. Miulli
-
Asti, Italie, 14100
- Ospedale Cardinal Massaia
-
Avellino, Italie, 83100
- Ospedale San Giuseppe Moscati di Avellino
-
Castelfranco Veneto, Italie, 31033
- Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale
-
Milan, Italie, 20141
- Istituto Europeo di Oncologia
-
Milan, Italie, 20132
- Ospedale San Raffaele di Milano
-
Naples, Italie, 80138
- Fondazione G Pascale Istituto Nazionale Tumori IRCCS
-
Ravenna, Italie, 48121
- Ospedale S. Maria Delle Croci
-
Rome, Italie, 00128
- Istituto Nazionale Tumori Regina Elena
-
-
-
-
-
Fuji-shi, Japon, 417-8567
- Fuji City General Hospital
-
Kanazawa, Japon, 920 8641
- Kanazawa University Hospital
-
Kashihara-shi, Japon, 634-8522
- Nara Medical University Hospital
-
Kisarazu-shi, Japon, 292-8535
- Kimitsu Chuo Hospital
-
Kobe, Japon, 650 0047
- Kobe City Medical Center General Hospital
-
Kumamoto, Japon, 860-0008
- National Hospital Organization Kumamoto Medical Center
-
Nagano, Japon, 381-8551
- Nagano Municipal Hospital
-
Nagasaki, Japon, 852-8501
- Nagasaki University Hospital
-
Nagasaki, Japon, 852-8511
- JRC Nagasaki Genbaku Hospital
-
Narashino-shi, Japon, 275-8580
- Saiseikai Narashino Hospital
-
Toon-shi, Japon, 791-0295
- Ehime University Hospital
-
Toyama, Japon, 930 0194
- Toyama University Hospital
-
Ube, Japon, 755-8505
- Yamaguchi University Hospital
-
Yokohama, Japon, 232 0024
- Yokohama City University Medical Center
-
-
-
-
-
Coimbra, Le Portugal, 3000-075
- Ipo Coimbra
-
Lisbon, Le Portugal, 1769 001
- Uls Santa Maria - Hosp. Santa Maria
-
Vila Nova de Gaia, Le Portugal, 4434 502
- Uls Gaia Espinho
-
-
-
-
-
Mexico City, Mexique, 14308
- Consultorio Medico dentro del Hospital Angeles Acoxpa
-
Monterrey, Mexique, 64460
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
Monterrey, Mexique, 64710
- Avix Investigacion Clinica S C
-
Mérida, Mexique, 97000
- Eme Red Hospitalaria
-
San Luis Potosí City, Mexique, 78260
- Oncologico Potosino
-
-
-
-
-
Hoofddorp, Pays-Bas, 2134 TM
- Spaarne Gasthuis
-
Nijmegen, Pays-Bas, 6524 KD
- Canisius-Wilhelmina Ziekenhuis
-
Nijmegen, Pays-Bas, 6525 GA
- Radboud Umcn
-
-
-
-
-
Bialystok, Pologne, 15 276
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Pologne, 85 048
- IN VIVO Sp. z o.o
-
Lublin, Pologne, 20 708
- Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
-
Piotrkow Trybunalski, Pologne, 97 300
- Centrum Medyczne
-
Poznan, Pologne, 61 731
- Clinical Research Center sp z o o MEDIC R s k
-
Słupsk, Pologne, 76-200
- Wojewodzki Szpital Specjalistyczny im Janusza Korczaka
-
Warsaw, Pologne, 02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Warsaw, Pologne, 02-647
- Provita Poliklinika
-
Wroclaw, Pologne, 50 556
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Edinburgh, Royaume-Uni, EH4 2XU
- Western General Hospital
-
London, Royaume-Uni, W6 8RF
- Charing Cross Hospital
-
London, Royaume-Uni, SW3 6JJ
- The Royal Marsden NHS Trust
-
London, Royaume-Uni, EC1A 7BE
- St Bartholomews Hospital
-
Plymouth, Royaume-Uni, PL6 8DH
- Derriford Hospital
-
Scunthorpe, Royaume-Uni, DN15 7BH
- Scunthorpe General Hospital
-
Sheffield, Royaume-Uni, S10 2JF
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Stevenage, Royaume-Uni, SG1 4AB
- Lister Hospital
-
Truro, Royaume-Uni, TR1 3LJ
- Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
-
-
-
-
-
Kaohsiung City, Taïwan, 833
- Chang Kung Memorial Hospital
-
Kaohsiung City, Taïwan, 807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung, Taïwan, 404
- China Medical University Hospital
-
Taichung, Taïwan, 40705
- Taichung Veterans General Hospital
-
Taipei, Taïwan, 11217
- Taipei Veterans General Hospital
-
Taoyuan, Taïwan, 33382
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Brno, Tchéquie, 65691
- Fakultni nemocnice u sv. Anny v Brne
-
Hradec Králové, Tchéquie, 500 05
- Fakultni nemocnice Hradec Kralove
-
Liberec, Tchéquie, 460 01
- Krajská nemocnice Liberec a.s.
-
Olomouc, Tchéquie, 779 00
- Fakultni nemocnice Olomouc
-
Prague, Tchéquie, 100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Prague, Tchéquie, 15006
- Fakultni nemocnice v Motole
-
Prague, Tchéquie, 140 59
- Thomayerova nemocnice, Onkologicka klinika
-
-
-
-
Arizona
-
Scottsdale, Arizona, États-Unis, 85259
- Mayo Clinic
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72211
- Arkansas Urology
-
-
California
-
Long Beach, California, États-Unis, 90822
- VA Long Beach Health Care System
-
Los Alamitos, California, États-Unis, 90720
- Genesis Research, LLC - West Coast Urology
-
Los Angeles, California, États-Unis, 90048
- Cedars Sinai Medical Center
-
Sacramento, California, États-Unis, 95630
- UC Davis Comprehensive Cancer Center
-
San Diego, California, États-Unis, 92123
- Genesis Research
-
Santa Monica, California, États-Unis, 90404
- Providence Saint Johns Cancer Institute
-
Santa Rosa, California, États-Unis, 95403
- Providence Medical Foundation
-
-
Colorado
-
Lakewood, Colorado, États-Unis, 80228
- Colorado Clinical Research
-
-
Florida
-
Hialeah, Florida, États-Unis, 33016
- Urological Research Network
-
Orlando, Florida, États-Unis, 32806
- Orlando Health Cancer Institute
-
Sarasota, Florida, États-Unis, 34239
- Sarasota Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30303
- Grady Memorial Hospital
-
Atlanta, Georgia, États-Unis, 30322
- The Emory Clinic Department of Urology
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University
-
Lisle, Illinois, États-Unis, 60532
- Duly Health and Care
-
Quincy, Illinois, États-Unis, 62301
- Blessing Hospital
-
-
Indiana
-
Carmel, Indiana, États-Unis, 46032
- Urology of Indiana
-
Jeffersonville, Indiana, États-Unis, 47130
- First Urology
-
-
Kansas
-
Merriam, Kansas, États-Unis, 66204
- AMR Kansas City Oncology
-
Wichita, Kansas, États-Unis, 67226
- Wichita Urology Group
-
-
Maryland
-
Hanover, Maryland, États-Unis, 21076
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Burlington, Massachusetts, États-Unis, 01805
- Lahey Hospital & Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- University Of Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68114
- The Urology Center, PC
-
-
New Jersey
-
Camden, New Jersey, États-Unis, 08103
- Cooper Health System MD Anderson Cancer Center at Cooper
-
-
New York
-
New York, New York, États-Unis, 10029
- Icahn School of Medicine at Mt. Sinai
-
New York, New York, États-Unis, 10010
- VA NY Harbor Healthcare System
-
Syracuse, New York, États-Unis, 13210
- SUNY Upstate Med Univ
-
Syracuse, New York, États-Unis, 13210
- Associated Medical Professionals of Ny
-
-
North Carolina
-
Greenville, North Carolina, États-Unis, 27834
- Vidant Urology - Greenville
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic
-
Gahanna, Ohio, États-Unis, 43230
- Central Ohio Urology Group
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, États-Unis, 19004
- Centers for Advanced Urology LLC d b a MidLantic Urology
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- UPMC Shadyside Hospital
-
-
South Carolina
-
Myrtle Beach, South Carolina, États-Unis, 29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt University Medical Center
-
Nashville, Tennessee, États-Unis, 37209
- Urology Associates
-
-
Texas
-
Austin, Texas, États-Unis, 78745
- Urology Austin
-
Dallas, Texas, États-Unis, 75231
- Urology Clinics of North Texas
-
Houston, Texas, États-Unis, 77030
- Houston Methodist Hospital
-
Houston, Texas, États-Unis, 77027
- Houston Metro Urology
-
San Antonio, Texas, États-Unis, 78229
- Urology San Antonio Research
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute
-
Salt Lake City, Utah, États-Unis, 84148
- George E. Wahlen VAMC
-
-
Virginia
-
Virginia Beach, Virginia, États-Unis, 23462
- Urology Of Virginia, Pllc
-
-
Washington
-
Spokane, Washington, États-Unis, 99202
- Spokane Urology
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ [CIS]), in participants who are Bacillus Calmette Guérin (BCG)-naïve
- BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
- All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma [HGUC]) for patients with papillary only disease (without CIS)
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to date of randomization
- Participants must be willing to undergo all study procedures
Exclusion Criteria:
- Presence or history of histologically confirmed, muscle invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to [>=] T2)
- Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to randomization
- Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. Participants with tumors involving the prostatic urethra in men will be excluded
- A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (mL)
- Indwelling catheters are not permitted; however, intermittent catheterization is acceptable
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment Group A: TAR-200 + Cetrelimab
Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab. |
Cetrelimab will be administered.
Autres noms:
TAR-200 will be administered intravesically.
Autres noms:
|
|
Comparateur actif: Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture
Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance). |
BCG will be administered intravesically. |
|
Expérimental: Treatment Group C: TAR-200 Alone
Participants will receive intravesical TAR-200 alone once Q3W. |
TAR-200 will be administered intravesically.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Event-free Survival (EFS)
Délai: Up to 5 years 2 months
|
EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to [>=] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first. |
Up to 5 years 2 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Complete Response (CR) Rate
Délai: Up to 5 years 2 months
|
Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months. |
Up to 5 years 2 months
|
|
Duration of CR
Délai: Up to 5 years 2 months
|
Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR. |
Up to 5 years 2 months
|
|
Recurrence-Free Survival (RFS)
Délai: Up to 5 years 2 months
|
RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first. |
Up to 5 years 2 months
|
|
Time to Progression (TTP)
Délai: Up to 5 years 2 months
|
TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first. |
Up to 5 years 2 months
|
|
Overall Survival (OS)
Délai: Up to 5 years 2 months
|
OS is defined as the time from randomization to death, due to any cause. |
Up to 5 years 2 months
|
|
Cancer Specific Survival (CSS)
Délai: Up to 5 years 2 months
|
CSS is defined as the time from randomization to the date of death due to bladder cancer. |
Up to 5 years 2 months
|
|
Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE)
Délai: Up to 5 years 2 months
|
Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event. |
Up to 5 years 2 months
|
|
Number of Participants with Adverse Events (AEs)
Délai: Up to 5 years 2 months
|
Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. |
Up to 5 years 2 months
|
|
Number of Participants with Change from Baseline in Laboratory Abnormalities
Délai: Up to 5 years 2 months
|
Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event. |
Up to 5 years 2 months
|
|
Number of Participants with Change from Baseline in Vital Signs Abnormalities
Délai: Up to 5 years 2 months
|
Number of participants with change from baseline in vital signs (blood pressure [systolic and diastolic], heart rate, temperature, and weight) abnormalities will be reported. |
Up to 5 years 2 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24
Délai: Up to 5 years 2 months
|
EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). |
Up to 5 years 2 months
|
|
Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores
Délai: Up to 5 years 2 months
|
EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). |
Up to 5 years 2 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CR109223
- 2020-004506-64 (Numéro EudraCT)
- 17000139BLC3002 (Autre identifiant: Janssen Research & Development, LLC)
- 2023-507187-39-00 (Identificateur de registre: EUCT number)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .